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Material/methods: Dosimeters (1 x 1 x 4.5 cm3) of varying 
chemical compositions were produced. They contained leuco-
malachite green (LMG) dye as the active component, 
chloroform and silicone elastomer.  
Twelve different batches were irradiated with 60 MeV proton 
beams, using a 40 mm circular collimator, to different doses 
(0 – 30 Gy). Irradiations were performed with both a low and 
a high dose rate (0.23 and 0.55 Gy/s). For comparison, 
depth–dose distributions were measured in water with a 
Markus-type, plane-parallel ionization chamber. 
Simultaneously, dosimeters from the same batches were 
irradiated with 6 MV photon beams in a 10 cm square field on 
a linear accelerator. 
All dosimeters were read out before irradiation and four 
hours after, at a wavelength of 635 nm. The read-out was 
performed with a home-built 1D-scanner with a depth 
resolution of 0.2 mm for the proton irradiated dosimeters, 
while a spectrophotometer was used for the photon read-out. 
The dose-rate dependency was compared for proton and 
photon irradiations. The ratio of Bragg-peak to plateau 
response (at 1 cm) was compared between batches. 
Results: The effect of lowering the dose rate was similar for 
proton and photon beams, although the beam qualities were 
different. The dose response was higher at a low dose rate, 
but at increasing dye concentration the effect was reduced. 
Significant under-response was observed in the Bragg peak. 
The peak-to-plateau ratio was improved from (2.5 ± 0.1) to 
(3.0 ± 0.04) by increasing the dye concentration from 0.1 to 
0.3 % (w/w). By increasing the curing-agent concentration 
from 5 to 9 % (w/w), the ratio further improved to (3.7 ± 0.4) 
and (3.5 ± 0.1) for the same respective dye concentrations.  
Conclusion: The 3D radiochromic silicone based dosimeter 
has for the first time been investigated in proton beams, and 
it was demonstrated that chemical modifications could 
influence the dosimeter response. 
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Purpose: There is interest in the particle therapy community 
to use prompt gammas (PG), a natural byproduct of particle 
treatment, for range verification and eventually dose control 
(Knopf et al. 2015). However, PG production is a rare process 
and therefore estimating PGs exiting a patient during a 
proton treatment plan executed by a Monte-Carlo simulation 
converges slowly. Recently, different approaches to 
accelerating the estimation of PG yield have been presented. 
Sterpin et al. (2015) described an analytic method that is 
about to be implemented in a commercial product, but has 
as drawback sensitivity to heterogeneities. Kanawati et al. 
(2015) described a variance reduction method (pgTLE) that 
accelerates the PG estimation by precomputing PG 
production probabilities as a function of energy and target 
materials, but has as drawback that it only works for 
analytical phantoms. 
Materials/Methods: We present a two-stage method, 
voxellized pgTLE (vpgTLE) that extends pgTLE to voxellized 
volumes. PG production probabilities are precomputed once, 
stored, and reused. In stage one, we simulate the 
interactions between the treatment plan and the patient CT 
with low statistic MC to obtain the spatial and spectral 
distribution of the PGs. As primary particles are propagated 
throughout the patient CT, the PG yields are computed in 
each voxel from the initial database, as function of the 
current energy of the primary, the material in the voxel and 
the step length. The result is a voxellized PG yield image, 
normalized to a single primary. The second stage uses the 
intermediate PG image as a source to generate and 
propagate PGs throughout the rest of the scene geometry, 
e.g. into a detection device, proportional to the number of 
primaries desired. 
Results: We have achieved a global speed-up of around 103 
for a heterogeneous phantom, for a 2% relative uncertainty 
on the PG yield. The method agrees with a reference Monte 
Carlo simulation to within 1% at the level of 2% relative 
uncertainty on the PG. Preliminary work on a full simulation 
of a clinical spot-scanning treatment plan and a patient CT 
image indicates a similar gain factor. Gains per voxel range 
from 102 to 105. 
Conclusion: We presented a generic PG yield estimator, drop-
in usable with any geometry and beam configuration. We 
showed a gain of around three orders of magnitude compared 
to analog MC. With a large number of voxels and materials, 
memory consumption may be a concern and we will discuss 
the consequence and possible trade-offs. The method will be 
available in the next release of Gate. 
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Metabolic Tumour Volume (MTV) is defined as the volume on 
FDG-PET/CT with increased FDG uptake. MTV has been shown 
to be of superior prognostic value compared to SUVmax in 
NSCLC. This study aims to explore the spatial overlap 
between CT-derived Gross Tumour Volume (GTV) and FDG-
PET/CT derived MTV. The second aim was to investigate the 
impact of this overlap on progression-free survival (PFS) and 
overall survival (OS). 
This was a single institution review performed in South 
Western Sydney, Australia. Inclusion criteria included proven 
NSCLC, stage I-III disease, radical radiotherapy and received 
PET imaging no more than 105 days before Tx. All FDG-PET 
